Login to get immediate access to this content.
LoginSpeaker: Fatima Cardoso, Portugal
#ESMO23: Breaking Science in Breast Cancer Video Series
Highlights on early-stage high-risk ER+/HER2 breast cancer: The KEYNOTE-756 study
Abstract discussed:
- LBA21 - KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published on 24 Oct 2023
